Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →To evaluate biotech executive pay, read the company’s latest definitive proxy statement (DEF 14A) as a connected set of disclosures: the Compensation Discussion and Analysis (CD&A) explains the committee’s rationale, the compensation tables show reported values and outcomes, and award terms and footnotes reveal the conditions behind them. Separate grant-date values from compensation actually paid and from what executives could ultimately realize; then assess the goals, vesting, peer group, company stage and potential dilution. A large equity grant alone does not show that pay was earned, that goals were demanding or that shareholders benefited.
Which proxy statement sections should you read?
Start with the latest definitive proxy statement filed by the issuer. Read the following sections together rather than treating a single compensation figure as the whole story:
As an Amazon Associate I earn from qualifying purchases.
- Compensation Discussion and Analysis (CD&A): the committee’s explanation of the program’s objectives, decisions, performance measures, peer comparisons and use of discretion.
- Summary Compensation Table: reported compensation, including salary, incentive compensation and equity grant-date values.
- Grants of Plan-Based Awards: the terms and potential ranges of annual incentives and equity awards granted during the year.
- Outstanding Equity Awards: options and other awards that remain unvested or unexercised at year-end.
- Option Exercises and Stock Vested: options exercised and equity that vested during the year, which can differ substantially from the original grant-date value.
- Potential Payments upon Termination or Change in Control: severance, acceleration and other payments that may apply in specified circumstances.
- Pay Versus Performance: a standardized multi-year comparison of compensation measures and selected performance measures.
Use the footnotes and award agreements where available to clarify vesting, performance conditions, settlement, forfeiture, valuation assumptions and other details that summary rows may not make obvious.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What do the different compensation figures mean?
Three measures answer different questions. Do not treat them as interchangeable.
#1 Best Overall
| Measure | What it tells you | What it does not establish by itself |
|---|---|---|
| Grant-date compensation | The values reported when compensation is granted, including equity awards valued at grant under SEC reporting rules. | What the executive ultimately receives. Equity value can rise, fall, expire unearned or remain unvested. |
| SEC-defined compensation actually paid | A prescribed Pay Versus Performance calculation that starts with Summary Compensation Table totals and adjusts for specified pension and equity-award values. | Cash received, or a complete account of the executive’s eventual proceeds. The measure is not simply cash paid. |
| Realized or realizable compensation | Realized pay generally reflects value received through events such as vesting or option exercise; realizable pay estimates value available under a stated valuation date and method. | A directly comparable figure across companies unless the definition, time period and valuation method are understood. |
When comparing a CEO’s compensation with company results, identify the measure, valuation date and period in each figure. A grant-date award can look large even if performance-based awards later pay nothing; conversely, an award may gain substantial value after grant if the share price rises.
How do options, RSUs and PSUs differ?
Equity instruments expose executives to different combinations of stock-price risk, performance risk and retention incentives. The award’s name is not enough: check the grant terms and the number of shares or units.
| Award | How value is created | What to inspect |
|---|---|---|
| Stock options | An option generally has no intrinsic value when the share price is below its exercise price. It can become valuable if the stock rises above the strike price while the option remains exercisable. | Exercise price; vesting schedule; expiration; current share price relative to the strike; repricing provisions; and the assumptions used for grant-date valuation. |
| Restricted stock units (RSUs) | RSUs can retain stock-linked value as they vest, even if the share price has fallen from its grant-date level. | Number of shares; time-based or other vesting conditions; settlement; forfeiture rules; and dividend equivalents. |
| Performance stock units (PSUs) or performance shares | Payout depends on results against specified performance conditions and may be zero if threshold goals are missed. | Metrics and weights; performance period; threshold, target and maximum; payout curve; peer group; absolute-return gates; caps; and committee discretion. |
Krystal Biotech’s 2026 proxy explains that its options provide value only if its common-stock price exceeds the exercise price, while its RSUs retain value and vest over time. That is a company-specific description, not a guarantee about another issuer’s award design.
How should you assess annual cash bonuses and performance goals?
For annual cash incentives and PSUs, test whether the disclosed goals make it possible to understand what performance earns a payout. Biotech measures may include financial results, shareholder returns, clinical or pipeline progress, regulatory or commercial milestones, business development, or other strategic objectives. Their relevance depends on the company’s stage and business model.
- Identify the metric, its weight and the performance period.
- Look for threshold, target and maximum performance, plus the payout curve or other explanation of how results translate into an award.
- Check whether the committee certifies results and whether goals are pre-set, measurable and specific enough for a reader to assess.
- Note any absolute-return gates, caps, peer-relative comparisons, adjustments for unusual items or committee discretion.
- Compare the target opportunity with the actual bonus paid or equity earned over multiple years, and look for explanations of special awards or changes to prior commitments.
A pipeline milestone can matter to a development-stage company without automatically representing shareholder value. Ask whether the milestone was achieved as defined, how it was assessed, and whether the payout design recognizes both success and failure. A PSU label alone does not establish that a plan is meaningfully pay-for-performance.
How does biotech stage affect the evaluation?
A clinical-stage biotech may have little product revenue or earnings, so its compensation plan may emphasize pipeline progress, clinical development, regulatory work or other strategic priorities. A company that has recently begun selling a product may add revenue or other commercial measures. Compare the objectives with the issuer’s operating stage, and distinguish progress toward a milestone from the value shareholders ultimately receive.
Rank #3
Cytokinetics’ 2026 proxy says the company received its first drug approval in December 2025 and began commercial sales in January 2026; it also reports no company-selected financial measure in its Pay Versus Performance disclosure. The example shows why a reader may need to consider strategic and pipeline progress alongside near-term financial measures during a transition to commercialization. It does not establish that any particular measure or pay design is appropriate for other biotechs.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Are the peer group and benchmark useful?
Peer comparisons are informative only when the selected companies compete for similar talent or provide a meaningful business comparison. Examine whether peers resemble the issuer in stage, size, therapeutic focus, geography and talent market. Then check how the committee used the data: a peer list alone does not show that compensation is fair or that the comparison drove a decision.
Krystal Biotech’s 2026 proxy describes the compensation committee’s use of peer-company information and a compensation consultant, as well as its consideration of executives’ outstanding equity, burn rate and potential dilution when setting awards. Adaptimmune Therapeutics’ 2026 proxy describes a move toward a market-median target philosophy. These are company-reported approaches, not independent validation of their benchmark choices.
Rank #4
What should you look for in Pay Versus Performance?
The SEC’s October 11, 2022 small-entity compliance guide explains the Item 402(v) requirements. The rules apply to reporting companies filing proxy or information statements that require executive compensation disclosure, with stated exclusions including foreign private issuers, registered investment companies and emerging growth companies.
The table generally covers five completed fiscal years for registrants other than smaller reporting companies (SRCs), and three years for SRCs. It reports total compensation and SEC-defined compensation actually paid for the principal executive officer (PEO), and an average for other named executive officers. Required comparisons include company cumulative total shareholder return (TSR), peer-group TSR for registrants other than SRCs, and net income. Non-SRCs also report a company-selected financial measure and list three to seven important financial performance measures. The disclosure is tagged in Inline XBRL.
Use the table to compare trends, not to deliver a standalone verdict. The prescribed compensation calculation includes specified valuation adjustments and does not measure only cash received; the standardized comparisons also do not, by themselves, explain scientific execution or the terms of every award. Read the company’s accompanying explanation and the relevant award terms.
How can you evaluate share usage and dilution?
Equity pay has consequences beyond the dollar value assigned to an executive’s grant. Consider the number of shares granted, the company’s available share pool, annual share usage or burn rate, existing unvested awards and the potential dilution from future or outstanding awards. Compare those figures with the company’s share base and stated retention or performance objectives. A grant’s reported value alone does not show its impact on other shareholders.
What do recent proxy examples show—and not show?
Issuer filings can illustrate how plans work, but examples should not be mistaken for industry-wide benchmarks. Adaptimmune Therapeutics’ 2026 proxy describes a standard executive equity mix of 50% RSUs and 50% PSUs. Its 2026 PSU measures—relative TSR and MRD revenue CAGR—each carry a 50% weight over a three-year period. The filing states that its most recent say-on-pay vote received 98.8% support. Those figures describe Adaptimmune’s disclosed design and vote, not a biotech-wide norm or independent proof of plan quality.
Incyte’s 2026 proxy describes annual cash incentives tied to commercial, R&D, business-development and ESG goals, alongside time-based and performance-based equity. Biogen’s 2026 proxy reports that certain performance-share cycles expired with no value after threshold goals were not achieved, and discusses changes to its performance-share design following shareholder feedback. It also compares CEO realizable pay with target pay: the proxy says realizable pay from the CEO’s 2022 hire through the end of 2025 was 48% lower than target pay awarded over that period. The same filing reports a $16.8 million grant-date value for CEO new-hire PSUs that the company says expired unearned in December 2025. These are company-reported outcomes and valuation descriptions, not neutral assessments of goal difficulty or fairness.
Free tools Windows power users keep installed
One-click scans. No signup required.
What questions should you answer before forming a view?
- What does the committee say the program is designed to achieve, and does the mix of salary, annual cash incentives and long-term equity fit that objective?
- What was targeted, earned, vested or forfeited, and over what period?
- Were goals, thresholds and payout rules disclosed clearly enough to judge? What role did committee discretion play?
- Are the peers comparable in stage, size, therapeutic focus, geography and talent competition, and does the proxy explain how benchmarks influenced pay?
- What do share usage, existing unvested awards and potential dilution imply for shareholders?
- How do TSR and the peer comparison relate to executive compensation actually paid, and what does the table’s valuation method leave out?
- Are severance, change-in-control or accelerated-vesting terms material to potential payments?
- How did shareholders vote on say-on-pay, and what specific design changes did the board make in response?
Proxy statements are issuer disclosures of the board’s and management’s rationale, not independent verification that targets were difficult or that pay was fair. For a specific company, base the assessment on its latest filing, award terms, operating stage, share price, capital needs, dilution and voting history.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
